The control of hyperphosphataemia in haemodialysis patients.
Patients with chronic uraemia develop various metabolic abnormalities, the most significant being the low production of vitamin D [1.25(OH)2D3] by the kidneys (1-3), hyperphosphataemia, and hypocalcaemia (4). These abnormalities, occurring usually in combination, are responsible for the pathogenesis of secondary hyperparathyroidism (HPT) (5-11). Prevention and treatment of secondary HPT can be achieved by means of administration of vitamin D and calcium. However, the above treatment is conditional on a low serum phosphorus concentration.
Papayianni
L
L
Nurse of Renal Unit, University Hospital of Ioannina, Greece.
Katopodis
K
K
Kosmanou
J
J
Banioti
A
A
Katsaraki
A
A
Palatzidou
M
M
Prokopiou
F
F
Betsiou
V
V
Siamopoulos
K C
KC
D000328:Adult; D000368:Aged; D000536:Aluminum Hydroxide / Q000008:administration & dosage*; D000863:Antacids / Q000008:administration & dosage*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005247:Feeding Behavior; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications*
D000863:Antacids; D010710:Phosphates; D000536:Aluminum Hydroxide